Navigation Links
Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
Date:10/17/2007

come infected during pregnancy.

CMV infection affects 30 to 60 percent of the patients undergoing various transplant procedures, causing transplant rejection, serious illness and even death if untreated. Expensive antiviral drug therapy is used to control the disease, but does not eliminate the infection. Congenital CMV infection affects one out of every hundred infants, and causes severe consequences in about 3,600 infants and death in about 400 each year in the United States.

There is no approved vaccine against CMV. Vaccine approaches that result in predominantly antibody responses to CMV have not proven highly effective in transplant patients. Vaccine approaches using live, attenuated viruses can induce both antibody and cellular immune responses, but pose a potential safety concern, particularly for immunocompromised patients, of causing the disease they are intended to prevent. Vical's novel DNA vaccine approach is designed to induce both antibody and cellular immune responses against specific features of the CMV virus without the risk of causing CMV disease. Vical's vaccine has received orphan drug designation for hematopoietic stem cell transplant and solid organ transplant patients.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to c
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... BALTIMORE, Dec. 15 Champions Biotechnology, ... engaged in the development of advanced preclinical platforms ... of oncology drugs, today announced its financial results ... 2009. Full details of Company,s financial results ... www.championsbiotechnology.com . ,, Total revenues for the ...
(Date:12/15/2009)... -- The U.S. Food and Drug Administration (FDA) Endocrinologic ... yes, 4 no, and 1 abstention that AstraZeneca has ... support the use of CRESTOR® (rosuvastatin calcium) in individuals ... or equal to 50 years, women greater than or ... 130 mg/dL; hsCRP greater than or equal to 2.0 ...
(Date:12/15/2009)... 15 Dakim, Inc. and Alzheimer,s Weekly today ... Ones, Brain Health Contest, designed to help five seniors ... and Alzheimer,s disease. All five winners will receive a ... to help seniors preserve their brain health and the ... living communities across the country. ,, The ...
Breaking Medicine Technology:Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 55 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3Yerkes researchers propose ambitious new strategies for AIDS vaccine research 53971 1Yerkes researchers propose ambitious new strategies for AIDS vaccine research 53971 2Yerkes researchers propose ambitious new strategies for AIDS vaccine research 53971 3The hepatitis healing power of blueberry leaves 9519 1GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 1GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 2GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 3GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 4GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 5GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 6GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 7
... Up to 24 Hours After,Exposure to Anthrax, ... Targanta,Therapeutics Corporation announced today the results from ... therapy for treating,exposure to Bacillus anthracis, the ... Oritavancin, a novel semi- synthetic,lipoglycopeptide antibiotic for ...
... GTx, Inc., (NASDAQ:,GTXI) announced today that data from ... of Ostarine(TM) and from the ongoing Phase,III clinical ... treatment of multiple side effects of androgen,deprivation therapy ... Meeting of the American Society of Clinical Oncology ...
Other Medicine Technology:Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 2Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 3Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax 4GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
(Date:12/15/2009)... 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in ... announced that shareholders had approved all three resolutions that the Company had proposed at the ... , , Description of ... Votes Non-, ... For ...
(Date:12/15/2009)... 15 Our Lady of Lourdes Health Care ... hospitals, has agreed to pay the United States $7.95 ... the Justice Department announced today. The two hospitals are ... N.J., and Lourdes Medical Center of Burlington County (LMC) ... in a suit brought by a whistleblower, Tony Kite, ...
(Date:12/15/2009)... 800,000 doses have lower strength than needed for protection, ... Almost 800,000 children,s doses of H1N1 swine flu vaccine ... they have lost some potency, federal health officials said ... Control and Prevention, the company,s routine testing of the ... years found that four batches had lower than required ...
(Date:12/15/2009)... Pa., Dec. 15 4R Systems, Inc., ... chain solutions which help retailers significantly increase profits ... decisions, announced today that The Vitamin Shoppe has ... ,, "4R,s store and DC inventory solutions have ... efficiency and in-stocks over the last two years," ...
(Date:12/15/2009)... BRAINTREE, Mass., Dec. 15 North American ... +3.9% in November year-over-year, according to the ... life insurance applications over the past three months ... 2009 levels of -1.6%, to flat at November,s ... recovering their interest in the benefits available from ...
Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3
... Clinics Struggle to Bridge GapsSAN FRANCISCO, Jan. 15 ... California show that the shortage among allied health workers ... organizations. This shortage is causing a number of problems ... clinic,s ability to serve more patients."Community clinics represent the ...
... 15 As today,s aging population spends increasing ... for mood-enhancing foods will continue to experience healthy ... worldwide consulting and research firm Kline & ... industry has so far focused mainly on physical ...
... increasingly turning to home care vs. assisted livingGLEN ELLYN, ... has affected all aspects of life, and long term ... sell their homes, moving to an assisted living facility ... option of aging-in-place with retrofits is growing in popularity ...
... in spite of their universal health care system which ... the United Kingdom are less willing to undergo dementia ... Britons perceive greater societal stigma from diagnosis of the ... older adults in Indianapolis and 120 older adults in ...
... Deceptive Advertising ClaimsNEW YORK, Jan. 15 A class ... States District Court for the Northern District of California ... deceptive advertising in marketing its VitaminWater line of beverages. ... Kallas, LLC ("WDK"), Reese Richman LLP, and the Center ...
... Company announced today it has agreed to plead guilty ... billion in criminal and civil fines, penalties and damages ... the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded ... for its blockbuster atypical antipsychotic, Zyprexa. The settlement ...
Other Medicine News:Health News:Allied Health Worker Shortage Strains Community Clinics 2Health News:Allied Health Worker Shortage Strains Community Clinics 3Health News:Mood-Enhancing and Heart Health Foods Emerging as Incidence of Heart Diseases Rises 2Health News:Mood-Enhancing and Heart Health Foods Emerging as Incidence of Heart Diseases Rises 3Health News:Housing Crisis Affects Seniors Needing Care 2Health News:Housing Crisis Affects Seniors Needing Care 3Health News:Does universal health care affect attitude toward dementia? 2Health News:Coca-Cola Sued Over Deceptive VitaminWater Claims 2Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 2Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 3Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 4
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
...
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
Medicine Products: